PCSAProcessa Pharmaceuticals, Inc.

Nasdaq processapharmaceuticals.com


$ 1.31 $ 0.03 (2.34 %)    

Monday, 09-Sep-2024 11:14:21 EDT
QQQ $ 455.04 $ 2.51 (0.55 %)
DIA $ 410.10 $ 2.77 (0.68 %)
SPY $ 547.24 $ 2.58 (0.47 %)
TLT $ 100.07 $ 0.69 (0.69 %)
GLD $ 231.25 $ -0.01 (-0 %)
$ 1.28
$ 1.29
$ 1.30 x 100
-- x --
$ 1.29 - $ 1.31
$ 1.28 - $ 18.00
24,759
na
4.17M
$ 1.05
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2024 06-30-2024 10-Q
2 05-10-2024 03-31-2024 10-Q
3 03-29-2024 12-31-2023 10-K
4 11-13-2023 09-30-2023 10-Q
5 08-10-2023 06-30-2023 10-Q
6 05-15-2023 03-31-2023 10-Q
7 03-30-2023 12-31-2022 10-K
8 11-08-2022 09-30-2022 10-Q
9 08-11-2022 06-30-2022 10-Q
10 05-12-2022 03-31-2022 10-Q
11 03-30-2022 12-31-2021 10-K
12 11-12-2021 09-30-2021 10-Q
13 08-12-2021 06-30-2021 10-Q
14 05-13-2021 03-31-2021 10-Q
15 03-25-2021 12-31-2020 10-K
16 11-12-2020 09-30-2020 10-Q
17 08-05-2020 06-30-2020 10-Q
18 05-15-2020 03-31-2020 10-Q
19 03-06-2020 12-31-2019 10-K
20 11-14-2019 09-30-2019 10-Q
21 08-14-2019 06-30-2019 10-Q
22 05-14-2019 03-31-2019 10-Q
23 03-28-2019 12-31-2018 10-K
24 11-14-2018 09-30-2018 10-Q
25 08-14-2018 06-30-2018 10-Q
26 05-21-2018 03-31-2018 10-Q
27 04-16-2018 12-31-2017 10-K
28 11-20-2017 09-30-2017 10-Q
29 10-04-2017 06-30-2017 10-Q
30 10-04-2017 03-31-2017 10-Q
31 09-25-2017 12-31-2016 10-K
32 09-08-2017 09-30-2016 10-Q
33 08-30-2017 06-30-2016 10-Q
34 08-07-2017 03-31-2016 10-Q
35 06-19-2017 12-31-2015 10-K
36 12-01-2015 09-30-2015 10-Q
37 08-19-2015 06-30-2015 10-Q
38 05-15-2015 03-31-2015 10-Q
39 04-14-2015 12-31-2014 10-K
40 11-13-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 processa-pharma-q2-eps-101-beats-102-estimate

Processa Pharma (NASDAQ:PCSA) reported quarterly losses of $(1.01) per share which beat the analyst consensus estimate of $(1.0...

 hc-wainwright--co-reiterates-buy-on-processa-pharma-maintains-6-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Processa Pharma (NASDAQ:PCSA) with a Buy and maintains $6 pric...

 processa-pharmaceuticals-reports-preclinical-data-for-ngc-iri-delivers-more-cancer-killing-sn-38-molecules-to-tumor-than-irinotecan-and-onivyde-studies-support-potential-benefit-as-an-improved-treatment-with-fewer-side-effects

Delivers more cancer-killing SN-38 molecules to tumor than irinotecan and Onivyde®Studies support potential benefit as an impro...

 hc-wainwright--co-maintains-buy-on-processa-pharma-lowers-price-target-to-6

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Processa Pharma (NASDAQ:PCSA) with a Buy and lowers the price t...

 hc-wainwright--co-reiterates-buy-on-processa-pharma-maintains-8-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Processa Pharma (NASDAQ:PCSA) with a Buy and maintains $8 pric...

 processa-pharmaceuticals-announces-fda-clearance-of-ind-application-for-a-phase-2-clinical-trial-of-ngc-cap-in-breast-cancer

Open-label Phase 2 trial in breast cancer to begin this quarterInitial data expected mid-2025HANOVER, Md., July 30, 2024 (GLOBE...

 hc-wainwright--co-reiterates-buy-on-processa-pharma-maintains-8-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Processa Pharma (NASDAQ:PCSA) with a Buy and maintains $8 pric...

 processa-pharmaceuticals-announces-results-from-phase-1b-trial-of-next-generation-capecitabine-for-stage-iiiiv-gi-cancer-establishing-maximum-tolerated-dose-and-recommended-phase-2-dose-range

Eight of 12 evaluable patients (66.7%) had progression-free survival (PFS) ranging from 5 to 11 monthsAt the highest NGC-Cap do...

 hc-wainwright--co-reiterates-buy-on-processa-pharma-maintains-8-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Processa Pharma (NASDAQ:PCSA) with a Buy and maintains $8 pric...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION